HUMAN-IMMUNODEFICIENCY-VIRUS COUNSELING, TESTING, REFERRAL, AND PARTNER NOTIFICATION SERVICES - A COST-BENEFIT-ANALYSIS

被引:82
作者
HOLTGRAVE, DR
VALDISERRI, RO
GERBER, AR
HINMAN, AR
机构
关键词
D O I
10.1001/archinte.153.10.1225
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The Centers for Disease Control and Prevention (Atlanta, Ga) annually provides more than $100 million in funding to states, territories, and cities for the provision of human immunodeficiency virus (HIV) counseling, testing, referral, and partner notification (CTRPN) services. Given the size of this expenditure, it is important to consider the net benefits of this program activity. We compared the economic costs and benefits of publicly funded HIV CTRPN services. Methods: Standard methods for cost-benefit analysis were used. A societal perspective was employed. Major assumptions used in the base-case analysis included the following: (1) without public funding, the HIV CTRPN services would not be provided; (2) for every 100 HIV-seropositive persons identified and reached by CTRPN services, at least 20 new HIV infections are averted; and (3) for every $100 spent on direct and indirect costs of CTRPN services, approximately another $60 is spent on the ancillary costs of alerting people to HIV issues and CTRPN service availability. Sensitivity analyses were performed to explore the robustness of base-case results to these and other changes in model assumptions. Results: Under base-case assumptions, the combined direct, indirect, and ancillary costs of the CTRPN program in 1990 dollars were $188 217 600. At a 6% discount rate, the estimated economic benefits of this expenditure are $3 781 918 000. The resultant benefit-cost ratio is 20.09. Sensitivity analyses showed that the benefit-cost ratio is greater than 1 for all considered cases. Conclusions: This cost-benefit analysis strongly suggests that publicly funded CTRPN services result in a net economic gain to society.
引用
收藏
页码:1225 / 1230
页数:6
相关论文
共 29 条
[1]  
[Anonymous], 1990, MMWR MORB MORTAL WKL, V39, P380
[2]   THE ECONOMIC-IMPACT OF AIDS IN THE UNITED-STATES [J].
BLOOM, DE ;
CARLINER, G .
SCIENCE, 1988, 239 (4840) :604-610
[3]   BENEFITS AND COSTS OF HIV TESTING [J].
BLOOM, DE ;
GLIED, S .
SCIENCE, 1991, 252 (5014) :1798-1804
[4]   A CLINICIAN GUIDE TO COST-EFFECTIVENESS ANALYSIS [J].
DETSKY, AS ;
NAGLIE, IG .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (02) :147-154
[5]   HIGH-RISK SEXUAL-BEHAVIOR AND KNOWLEDGE OF HIV ANTIBODY STATUS IN THE SAN-FRANCISCO-CITY-CLINIC-COHORT [J].
DOLL, LS ;
OMALLEY, PM ;
PERSHING, AL ;
DARROW, WW ;
HESSOL, NA ;
LIFSON, AR .
HEALTH PSYCHOLOGY, 1990, 9 (03) :253-265
[6]   SCREENING BLOOD-DONORS FOR HUMAN IMMUNODEFICIENCY VIRUS-ANTIBODY - COST-BENEFIT-ANALYSIS [J].
EISENSTAEDT, RS ;
GETZEN, TE .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1988, 78 (04) :450-454
[7]  
FOX R, 1987, AIDS, V1, P241
[8]   DISEASE PREVENTION MODELS OF VOLUNTARY CONFIDENTIAL SCREENING FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) [J].
GAIL, MH ;
PRESTON, D ;
PIANTADOSI, S .
STATISTICS IN MEDICINE, 1989, 8 (01) :59-81
[9]  
Ganiats T G, 1991, Fam Med, V23, P457
[10]   EFFICACY OF PARTNER NOTIFICATION FOR HIV-INFECTION [J].
GIESECKE, J ;
RAMSTEDT, K ;
GRANATH, F ;
RIPA, T ;
RADO, G ;
WESTRELL, M .
LANCET, 1991, 338 (8775) :1096-1100